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at presentation have not been investigated so far in HLH.
Hence, we decided to retrospectively analyze lymphocyte
subsets and quantitative immunoglobulin levels in addi-
tional to traditional diagnostic markers at presentation in
patients with HLH.
Methods: We retrospectively analyzed the medical records
of patients who received a diagnosis of HLH at our institu-
tion, believed to be familial or secondary HLH. Patients with
SAP deﬁciency were excluded as hypogammaglobulinemia is
a known association. Patients who had received HLH therapy
prior to evaluation of lymphocyte subsets and immuno-
globulin levels were also excluded from the analysis. Data at
presentation was evaluable in 35 patients.
Results: Of the 35 patients, 26 had familial HLH and 9 had
secondary HLH. 25 patients underwent allogeneic HSCT.
Seven died secondary to complications post HSCT and 1
patient died prior to HSCT from refractory HLH. Identiﬁable
genetic mutations associated with HLH were found in 20
patients. Analysis of their immune phenotype in additional
to the diagnostic criteria revealed the following: 19(54%)
had B-cell lymphopenia, including 7(20%) who had both
T-cell and B-lymphopenia. 3(8%) patients had T-cell
lymphopenia. Even in patients with B and T cell lympho-
penia, the B-cell lymphopenia was proportionately lower.
Hypogammaglobulinemia (low IgG levels) was seen in 4
patients.
Discussion: Although we noted hypogammoglobulinemia in
a few patients, the predominant ﬁnding was the high inci-
dence of B-cell lymphopenia. Interestingly, B-cell lympho-
penia and hypogammaglobulinemia have also been noted
perforin deﬁcient mice with HLH at our institution (unpub-
lished data). In conclusion, this study suggests that B-cell
lymphopenia can serve as a surrogate marker for the diag-
nosis of HLH.243
Reduced-Intensity Conditioning and Umbilical Cord
Blood Transplantation in Children. Experience of a
Pediatric Hospital in Colombia
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Umbilical cord blood (UCB) has been shown to contain suf-
ﬁcient progenitor cells to provide durable engraftment in
children, and it provides an alternative stem cell source for
patients without matched related or unrelated donors.
We describe the preliminary results of a cohort of 16 pedi-
atric patients with a median age of 9 years (range 3 -18) with
haematological malignancies undergoing to a unrelated
umbilical cord blood transplant with a reduced-intensity
conditioning regimen of ﬂudarabine, melphalan, and
antithymocyte globulin.
All patients achieved hematologic recovery, the median
time to an absolute neutrophil count > 0.5 x 109/L was 20
days, and the median time to an unsupported platelet
count > 20 x 109/L was 32 days. Acute graft-versus-host
disease (GVHD) grade III-IV occurred in 37,5% of patients.
The 100-day TRM was 25%, and the 1 -year disease-free
survival was 58%.
Our ﬁndings support the use of reduced-intensity regimen in
pediatric patients with hematologic malignancies, however
the incidence of acute GVHD is a little higher than that re-
ported in other series so a better strategy for prophylaxis
against acute GVHD should be implemented.244
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X-linked adrenoleukodystrophy (X-ALD) is a demyelinating
disease caused by the deﬁciency of the ABCD1 gene that
encodes for a peroxisomal protein membrane. The most se-
vere form of X-ALD is the cerebral variant, which leads to
severe disability and death during the ﬁrst two decades. To
date, allogeneic hematopoietic stem cell transplantation
(HSCT) is the only treatment that has shown to signiﬁcantly
change the natural history of the disease, enhancing survival
and stabilizing neurological lesions and symptoms. In the
absence of a matched sibling or unrelated donor, hap-
loidentical family members might be an option in these
rapidly progressing diseases. Haploidentical HSCT has been
performed using a T cell depleted graft, but is often associ-
ated with higher rates of graft failure and delayed immune
reconstitution. Haploidentical HSCT using post-transplant
cyclophosphamide has been performed in series of malig-
nant and non-malignant diseases and has shown similar
outcomes compared to other alternative donor sources. Here
we show our experience with 8 patients with X-ALD treated
with haploidentical HSCT with post-transplant cyclophos-
phamide. Between november 2012 and august 2013, 8
patients with X-ALD (ages 6 to 18 years) underwent hap-
loidentical related HSCT in two different institutions, two
patients received two transplants with different related do-
nors. One patient received a second transplant after failure of
a double cord blood transplant. Pre-transplant MRI showed
Loes score of 2,5 to 18, all patients had neuropsychological
evaluation with performance IQ above 90. Donor was the
father (n¼7), the uncle (n¼2) or brother (n¼1). All patients
received reduced toxicity conditioning regimen consisted of:
ﬂudarabine 150 mg/m2, cyclophosphamide 29 mg/kg and
total body irradiation 2 Gy. Six patients received also rabbit
antithymocyte globulin 4,5 mg/kg. GVHD prophylaxis con-
sisted of cyclophosphamide 50 mg/kg/d on days +3 and +4,
tacrolimus and mycophenolate mofetil starting on day +5.
Seven patients engrafted, 13 to 19 days after transplant. One
patient had a primary graft failure and was not eligible for a
second transplant due to severe progression of neurological
symptoms. Two patients had secondary graft failure with
progressive loss of donor chimerism and were successfully
rescued with second haploidentical transplants using
different related donors. Four patients had grade II-IV acute
graft-versus-host disease and four patients had CMV reac-
tivations. One patient with grade III GVHD showed progres-
sion of neurologic symptoms of primary disease. Seven
patients are alive and engrafted from 3 to 11 months after
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conclusion, haploidentical HSCT with post-transplant cyclo-
phosphamide is a feasible alternative for X-ALD lacking a
suitable matched donor. Graft failure is still an obstacle that
has to be better prevented.245
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The standard of care for the transplantation of pediatric pa-
tients with acute leukemia and prior CNS disease is the use of
total body irradiation (TBI), plus a CNS radiation therapy (RT)
boost. However, the late effects of radiation can be pro-
hibitive, especially in younger children or those who have
previously received radiation therapy. We developed a
chemotherapy-only cytoreductive regimenwith the intent of
targeting the CNS with agents that can readily cross the
blood brain barrier and achieve high concentrations. We
used the combination of Busulfan (1mg/kg every 6 hours x 3
days), melphalan (50mg/m2/day x 2 days), and thiotepa IV
(8.3mg/kg/day or 250mg/m2/day x 2 days).
We treated six patients with acute myelogenous leukemia
(AML (N¼5) or acute lymphoblastic leukemia (ALL) with this
regimen from July 1999 and February 2013. The median age
at the time of HSCT was 2.8 years (range 1.7 to 13.4 years).
Patients were in complete CNS remission (CR) CR1 (N¼1),
CR2 (N¼3), CR3 (N¼1), and CR8 (N¼1). All six patients were
treated with multiple intrathecal chemotherapy agents prior
to transplant. Four of six patients received cranio-spinal
radiation therapy (RT) prior to HSCT; RT was required to
achieve a CNS CR in 3 of 4 of these patients. One patient
received CNS RT post HSCT, while one patient was
completely spared CNS RT.
Donors and grafts included unrelated mismatched umbilical
double cord transplants (N¼4) and matched related T-cell
depleted bone marrow transplants (N¼2). All six patients
engrafted. One patient succumbed to infectious complica-
tions nearly 2 months post HSCT. The ﬁve other patients are
still alive without marrow or CNS relapse at a median follow-
up of 19.4 months post HSCT (range: 11.1 to 149.5 months) .
While this represents a small patient series, this data pro-
vides evidence for a promising transplant chemotherapy-
only regimen for the transplantation of pediatric patients
with acute leukemia and CNS disease who are unable to
receive TBI, and will be the focus of a larger prospective
study.246
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2 Christian Medical College, Vellore, IndiaAcute GVHD (aGVHD) remains a major challenge in alloge-
neic stem cell transplantation and is associated with signif-
icant morbidity. Though it is associated with a graft versus
leukemia effect in SCT for malignant disorders, it has no
beneﬁt in SCT for non-malignant disorders such as thalas-
semia major.
This is a retrospective analysis of 321 patients who under-
went allogeneic SCT for Thalassemia Major at our centre
between Jan 1991 and Dec 2011. This included 205 males and
116 females with a median age of 7 years (range: 2 - 24).
Patients who expired prior to 2 weeks or had primary graft
rejection were excluded from this analysis. 6.9% of patients
were in Lucarelli Class I, 36.4% in Class II, and 56.7% in Class
III. Donors included matched sibling (n ¼ 299) or other
family donors (n ¼ 22). Conditioning regimen was predom-
inantly Busulfan based (n ¼ 274) while 47 patients received
treosulfan based conditioning. Graft source was mainly bone
marrow (n ¼ 286) while GVHD prophylaxis mainly was
Cyclosporine with short course methotrexate (n ¼ 301).
Acute GVHD (Grade I e IV) occurred in 125 patients (38.9%),
grade II-IV in 28% and grade IV in 5.3%. Donor age (p¼ 0.062),
type of conditioning regimen (p ¼ 0.07), number of doses of
methotrexate administered (p ¼ 0.05), presence of veno-
occlusive disease (VOD) [p ¼ 0.016] and time to neutrophil
engraftment (p ¼ 0.027) were found to be signiﬁcant risk
factors for acute GVHD on a univariate analysis but only VOD
(p ¼ 0.017) and donor age (p ¼ 0.044) remained signiﬁcant
on multivariate analysis. Resolution of GVHD was seen in
90.4% while 9.6% died either due to GVHD or infection. The
3 year overall survival was 80%  2.3% in patients with
GVHD compared to 81.1%  2.9% in patients without GVHD
(p ¼ 0.422).
Acute GVHD is seen in 39% of patients undergoing SCT for
thalassemia major but it does not have a signiﬁcant impact
on overall survival.247
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Background: Hemorrhagic cystitis (HC) is a fairly common
and potentially severe complication observed after hemato-
poietic Stem cell transplantation (HSCT) which may result in
morbidity and extended hospitalization. Its incidence in pe-
diatric patients is unknown.
Methods: We performed a retrospective study on 900 pe-
diatric patients who received HSCT after myeloablative or
reduced intensity conditioning during 1992 e 2011 in our
center. In all, sixty patients (43 male &17 female) developed
HC: early in 35 patients and late in 25 patients. Median age of
patients was 9.19years (range: 2-15). Major thaassemia (45%)
and ALL (18.30%) were most common cause of trans-
plantation. Patients received transplant frommatched donor
(n¼45), 2 locus mismatched (n¼8) and HLA-haploidentical
(n¼7). The source of stem cell were peripheral blood (n¼40),
bone marrow (n¼15) and cord blood (n¼5). Majority of pa-
tient (83.3%) received BU/CY conditioning regiment.
Results: The prevalence of HC was 6.7% in our patients who
all of them had received allogenic HSCT. 4 patients had
pervious history of HC. Acute graft versus host disease
(GvHD) occurred in 46(76.7%) patients. There was no sig-
niﬁcant correlation between the grade of acute GvHD and
